180 related articles for article (PubMed ID: 16450814)
41. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
Weir R; McMurray JJ
Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
[TBL] [Abstract][Full Text] [Related]
42. Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function.
Siu CW; Pong V; Jim MH; Yue WS; Ho HH; Li SW; Lau CP; Tse HF
Pacing Clin Electrophysiol; 2010 Jun; 33(6):675-80. PubMed ID: 20132502
[TBL] [Abstract][Full Text] [Related]
43. Clinical trial data on the cardioprotective effects of beta-blockade.
Kendall MJ
Basic Res Cardiol; 2000; 95 Suppl 1():I25-30. PubMed ID: 11192348
[TBL] [Abstract][Full Text] [Related]
44. A review of carvedilol arrhythmia data in clinical trials.
Kowey PR
J Cardiovasc Pharmacol Ther; 2005 Jun; 10 Suppl 1():S59-68. PubMed ID: 15965573
[TBL] [Abstract][Full Text] [Related]
45. Assessment and key targets for therapy in the post-myocardial infarction patient with left ventricular dysfunction.
Flaherty JD; Udelson JE; Gheorghiade M; Wu E; Davidson CJ
Am J Cardiol; 2008 Sep; 102(5A):5G-12G. PubMed ID: 18722186
[TBL] [Abstract][Full Text] [Related]
46. Percutaneous coronary intervention for myocardial infarction with left ventricular dysfunction.
Flaherty JD; Davidson CJ; Faxon DP
Am J Cardiol; 2008 Sep; 102(5A):38G-41G. PubMed ID: 18722190
[TBL] [Abstract][Full Text] [Related]
47. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STrategy plus ICD trial.
Raviele A; Bongiorni MG; Brignole M; Cappato R; Capucci A; Gaita F; Gulizia M; Mangiameli S; Montenero AS; Pedretti RF; Uriarte JA; Sermasi S; Nisam S;
Europace; 2005 Jul; 7(4):327-37. PubMed ID: 16028343
[TBL] [Abstract][Full Text] [Related]
48. Predicting and preventing sudden death from cardiac causes.
Gilman JK; Jalal S; Naccarelli GV
Circulation; 1994 Aug; 90(2):1083-92. PubMed ID: 7913885
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.
Shlipak MG; Browner WS; Noguchi H; Massie B; Frances CD; McClellan M
Am J Med; 2001 Apr; 110(6):425-33. PubMed ID: 11331052
[TBL] [Abstract][Full Text] [Related]
50. Medical therapy of acute myocardial infarction: Part II. The role of adjunctive medical therapy.
Jafri SM; Borzak S
J Intensive Care Med; 1995; 10(3):109-16. PubMed ID: 10155176
[TBL] [Abstract][Full Text] [Related]
51. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period.
Hjalmarson A
Am J Cardiol; 1997 Nov; 80(9B):35J-39J. PubMed ID: 9375948
[TBL] [Abstract][Full Text] [Related]
52. Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Reiffel JA
J Cardiovasc Pharmacol Ther; 2005 Jun; 10 Suppl 1():S45-58. PubMed ID: 15965572
[TBL] [Abstract][Full Text] [Related]
53. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery.
Bauer SM; Cayne NS; Veith FJ
J Vasc Surg; 2010 Jan; 51(1):242-51. PubMed ID: 19954922
[TBL] [Abstract][Full Text] [Related]
54. Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?
Squire I
Heart Fail Rev; 2004 Oct; 9(4):337-45; discussion 347-51. PubMed ID: 15886979
[TBL] [Abstract][Full Text] [Related]
55. Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period.
Borrello F; Beahan M; Klein L; Gheorghiade M
Rev Cardiovasc Med; 2003; 4 Suppl 3():S13-24. PubMed ID: 14564230
[TBL] [Abstract][Full Text] [Related]
56. Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devices.
Naccarelli GV
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I51-7. PubMed ID: 16450813
[TBL] [Abstract][Full Text] [Related]
57. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk.
Abraham WT
Rev Cardiovasc Med; 2003; 4 Suppl 3():S30-6. PubMed ID: 14564232
[TBL] [Abstract][Full Text] [Related]
58. [Secondary prevention after myocardial infarction].
Czuriga I
Orv Hetil; 2002 Sep; 143(37):2117-28. PubMed ID: 12434627
[TBL] [Abstract][Full Text] [Related]
59. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Barron HV; Michaels AD; Maynard C; Every NR
J Am Coll Cardiol; 1998 Aug; 32(2):360-7. PubMed ID: 9708461
[TBL] [Abstract][Full Text] [Related]
60. Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients.
Awada G; de Azambuja E; Awada A
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1205-1215. PubMed ID: 29088977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
